Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Opus Genetics (IRD) Debt to Equity (2019 - 2026)

Opus Genetics has reported Debt to Equity over the past 5 years, most recently at -$0.03 for Q1 2026.

  • Quarterly Debt to Equity fell 101.04% to -$0.03 in Q1 2026 from the year-ago period, while the trailing twelve-month figure was -$0.03 through Mar 2026, down 101.04% year-over-year, with the annual reading at $0.07 for FY2025, N/A changed from the prior year.
  • Debt to Equity was -$0.03 for Q1 2026 at Opus Genetics, down from $0.07 in the prior quarter.
  • Over five years, Debt to Equity peaked at $3.75 in Q3 2025 and troughed at -$0.03 in Q1 2026.
  • The 4-year median for Debt to Equity is $0.07 (2025), against an average of $1.01.
  • The largest YoY upside for Debt to Equity was 101.04% in 2026 against a maximum downside of 101.04% in 2026.
  • A 4-year view of Debt to Equity shows it stood at $0.01 in 2022, then plummeted by 85.14% to $0.0 in 2023, then surged by 3877.15% to $0.07 in 2025, then crashed by 135.53% to -$0.03 in 2026.
  • Per Business Quant, the three most recent readings for IRD's Debt to Equity are -$0.03 (Q1 2026), $0.07 (Q4 2025), and $3.75 (Q3 2025).